<DOC>
	<DOCNO>NCT02968121</DOCNO>
	<brief_summary>To determine pharmacokinetics , safety tolerability brexpiprazole administer subcutaneously intramuscularly adult schizophrenia .</brief_summary>
	<brief_title>Safety Tolerability Study Single-dose Administration Brexpiprazole Adult Subjects With Schizophrenia</brief_title>
	<detailed_description>This trial design assess pharmacokinetics , safety tolerability brexpiprazole treatment subject schizophrenia . The trial consist two part across 13-36 month . The trial population include approximately 110 male &amp; female subject 18 64 year age ( inclusive ) diagnosis schizophrenia define DSM-V criterion .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Brexpiprazole</mesh_term>
	<criteria>Males females 18 64 year age , inclusive , screen visit diagnosis schizophrenia define DSMV criterion . Body mass index 18 35 kg/m^2 screen visit . Good physical health determine clinically significant deviation normal . Ability provide inform consent and/or consent obtain legally acceptable representative ( require IRB ) , prior initiation protocolrequired procedure . Male female subject surgically sterile , female subject postmenopausal least 12 consecutive month prior screen visit , male subjects/female subject ( childbearing potential ) agree remain abstinent practice 2 approve birth control method screen visit least 150 day dose IMP female subject 180 day dose IMP male subject . Subjects : Met DSMV criterion substance use disorder within past 180 day ; include alcohol benzodiazepine , exclude caffeine/nicotine . A positive drug screen drug abuse ( exclude stimulant , prescribed medication , marijuana [ investigator 's documented opinion subject meet DSMV criterion substance use disorder ] ) . Use 1 psychotropic medication screen baseline visit , except oral brexpiprazole administer brexpiprazole tolerability testing ( applicable ) current oral antipsychotic medication . Use varenicline beyond screen . Subjects participate clinical trial involve psychotropic medication within 1 month prior administration IMP 5 halflives last IMP administration whichever longer . Subjects significant risk commit suicide base history , routine psychiatric status examination , investigator 's judgment , answer `` yes '' question 4 5 Baseline Version CSSRS . Subjects currently acute relapse schizophrenia assess investigator . Subjects current DSMV diagnosis schizophrenia . Also , subject borderline , paranoid , histrionic , schizotypal , schizoid , antisocial personality disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>